AML ETO t821 GENE REARRANGEMENT PCR QUALITATIVE Test
Test Cost: AED 1000.0
Introduction
The AML ETO t821 GENE REARRANGEMENT PCR QUALITATIVE Test is a diagnostic test offered by DNA Labs UAE. This test is used to detect the presence of a specific genetic rearrangement in patients with acute myeloid leukemia (AML).
Test Components
- Price: 1000.0 AED
- Sample Condition: 3 mL (2 mL min.) whole blood / Bone marrow from 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.
- Report Delivery: SampleMon / Thu by 11 am; ReportWed / Sat
- Method: Real Time PCR
- Test Type: Leukemia
- Doctor: Oncologist
- Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information
No special preparation is required before taking the AML ETO t821 GENE REARRANGEMENT PCR QUALITATIVE Test.
Test Details
The AML ETO t(821) gene rearrangement PCR qualitative test is specifically designed to detect the presence of a genetic rearrangement in AML patients. AML is a type of cancer that affects the bone marrow and blood cells.
The t(8;21) gene rearrangement is a specific chromosomal abnormality that is found in a subset of AML cases. This rearrangement involves the fusion of two genes, the AML1 gene on chromosome 21 and the ETO gene on chromosome 8.
The AML ETO t(821) gene rearrangement PCR qualitative test utilizes polymerase chain reaction (PCR) technology to amplify and detect the specific DNA sequence that indicates the presence of this gene fusion. It is a qualitative test, meaning it can determine whether the gene rearrangement is present or not, but it does not provide information about the quantity or level of the rearrangement.
This test is crucial in the diagnosis and monitoring of AML patients, as the presence of the t(8;21) gene rearrangement can influence treatment decisions and prognosis. By detecting this genetic abnormality, healthcare professionals can personalize treatment plans and predict patient outcomes more accurately.
Test Name | AML ETO t821 GENE REARRANGEMENT PCR QUALITATIVE Test |
---|---|
Components | |
Price | 1000.0 AED |
Sample Condition | 3 mL (2 mL min.) whole blood \/ Bone marrow from 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. |
Report Delivery | SampleMon / Thu by 11 am; ReportWed / Sat |
Method | Real Time PCR |
Test type | Leukemia |
Doctor | Oncologist |
Test Department: | MOLECULAR DIAGNOSTICS |
Pre Test Information | No special preparation required |
Test Details |
The AML ETO t(821) gene rearrangement PCR qualitative test is a diagnostic test used to detect the presence of a specific genetic rearrangement in acute myeloid leukemia (AML) patients. AML is a type of cancer that affects the bone marrow and blood cells. The t(8;21) gene rearrangement is a specific chromosomal abnormality that is found in a subset of AML cases. This rearrangement involves the fusion of two genes, the AML1 gene on chromosome 21 and the ETO gene on chromosome 8. The AML ETO t(821) gene rearrangement PCR qualitative test uses polymerase chain reaction (PCR) technology to amplify and detect the specific DNA sequence that is indicative of this gene fusion. It is a qualitative test, meaning it can determine whether the gene rearrangement is present or not, but it does not provide information about the quantity or level of the rearrangement. This test is important in the diagnosis and monitoring of AML patients, as the presence of the t(8;21) gene rearrangement can impact treatment decisions and prognosis. By detecting this genetic abnormality, healthcare professionals can tailor treatment plans and predict patient outcomes more accurately. |